BioPharma Drive: Drug Pricing
MAY 31, 2025
AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its importance as a second-line treatment option.
Drugs.com
MAY 31, 2025
SATURDAY, May 31, 2025 Stress from work doesnt always stay at the office and it may be affecting more than just your mood. A new study finds that your dog may be picking up on it, too, especially if you have a hard time letting go of work worri.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioPharma Drive: Drug Pricing
MAY 31, 2025
While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free survival was modest.
Perficient: Drug Development
MAY 31, 2025
We have been hearing about AI in many different ways and technology pioneers have been slowly introducing AI in our daily lives. When it comes to Fusion Applications, Oracle has invested in built-in AI capabilities across all platforms and Supply Chain area is not an exception. In this blog, I would like to discuss the newly designed Product Management Redwood Experience and a few AI capabilities that comes out of of the box.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
BioPharma Drive: Drug Pricing
MAY 31, 2025
The shot, dubbed mNexspike, is approved for older adults and people whose health conditions put them at higher risk of severe disease.
Chemical Biology and Drug Design
MAY 31, 2025
Despite significant research in the past decades, no EP4 antagonist has been approved for human use yet. The scaffold-hopping approach, in combination with docking studies, synthesis, and biological investigations, resulted in a nontoxic, potent compound 4 , which is metabolically stable, permeable, and orally bioavailable EP4 antagonist. ABSTRACT The prostaglandin E 2 (PGE 2 ) regulates several biological processes via interaction with 1 of 4 E-type prostanoid receptors (EP1EP4).
Expert insights. Personalized for you.
Let's personalize your content